RMAT: FDA started new expedited program for cell therapies

FDA recently introduced the new Regenerative Medicine Advanced Therapy (RMAT) Designation in the framework of the 21st Century Cures Act. This new FDA pathway enables companies developing cell- and tissue-based therapies, tissue-engineering products, and combination treatments to have earlier and more frequently interactions with the agency and benefit from proactive collaboration with FDA.